Ruptured hepatocellular carcinoma following administration of Lenvatinib: an autopsy case

DOI Web Site Web Site 22 References
  • Uchida Kumichika
    Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University
  • Aoyama Toru
    Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University
  • Terai Yuji
    Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University
  • Yamaguchi Naomi
    Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University
  • Kato Shingo
    Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University
  • Yakabi Koji
    Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University
  • Kikuchi Jun
    Department of Pathology, Saitama Medical Center, Saitama Medical University
  • Ogasawara Sachiko
    Department of Pathology, Kurume University School of Medicine
  • Yano Hirohisa
    Department of Pathology, Kurume University School of Medicine
  • Nagoshi Sumiko
    Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University

Bibliographic Information

Other Title
  • Lenvatinib短期投与の中止後に破裂した肝細胞癌の一剖検例
  • Lenvatinib タンキ トウヨ ノ チュウシ ゴ ニ ハレツ シタ カン サイボウ ガン ノ イチ ボウケンレイ

Search this article

Abstract

<p>Lenvatinib was prescribed to a 71-year-old man with hepatocellular carcinoma (210 mm, largest dimension) and portal vein tumor thrombosis. However, this treatment was discontinued 8 days later due to prolongation of prothrombin time and an increase in AST and LDH levels. Rupture of the hepatocellular carcinoma occurred 4 days after discontinuing Lenvatinib and the patient died. Autopsy findings showed a moderately differentiated hepatocellular carcinoma with diffuse hemorrhagic necrosis. Immunohistochemistry revealed diffuse FGF19 protein expression in the nuclei of tumor cells, whereas some of the nuclei and cytoplasm of the hepatocytes in non-tumorous tissue were only slightly stained. The risk of hepatocellular carcinoma rupture should always be considered even after stopping short-term chemotherapy with Lenvatinib.</p>

Journal

  • Kanzo

    Kanzo 63 (5), 238-245, 2022-05-01

    The Japan Society of Hepatology

References(22)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top